ROSMED Team (OOO RSMI), alumnus of Sber500 third batch, closed Round A and won USD 1.5 mn from an international investment company.
These funds enabled the start-up to open offices in Kazakhstan and Israel, win new contracts, and launch their international brand One Health. In 2023–2024, the company plans to enter other countries’ markets and raise additional investments in Round B.
These funds enabled the start-up to open offices in Kazakhstan and Israel, win new contracts, and launch their international brand One Health. In 2023–2024, the company plans to enter other countries’ markets and raise additional investments in Round B.
Natalia Magidey, managing director for Sber’s start-up ecosystem:
“We value Sber500 alumni success as it proves that our program aimed at consistent start-up promotion is effective. We congratulate the ROSMED team on yet another achievement and wish the company further growth both domestically and internationally. I am always happy and proud to see start-ups go through later growth stages, unfold their potential, and transform into mature companies that make a significant impact on the market in their countries of presence.”
ROSMED.INFO, an AI-driven online healthcare platform, is designed to collect and analyze medical information. The AI-driven medical online platform ROSMED.INFO collects and analyzes medical information. The platform contains patient records, laboratory diagnostic programs with real-time access to test results, and a social media network to connect doctors and patients. More than 6,000 doctors from 1,000+ medical institutions across Russia are already connected to the platform.
ROSMED is one of the Sber500 finalists and the Innovation Support Fund subsidee. The investments it received in Round A were utilized to create the Medical Decision-Making Support System (MDMSS) integrated with the medical ecosystem and helping doctors make the right decisions across various therapeutic areas, including atopic dermatitis, multiple sclerosis, deafness, and predict in vitro fertilization effectiveness prior to the procedure.
ROSMED is one of the Sber500 finalists and the Innovation Support Fund subsidee. The investments it received in Round A were utilized to create the Medical Decision-Making Support System (MDMSS) integrated with the medical ecosystem and helping doctors make the right decisions across various therapeutic areas, including atopic dermatitis, multiple sclerosis, deafness, and predict in vitro fertilization effectiveness prior to the procedure.